| Symbol | MNPR |
|---|---|
| Name | MONOPAR THERAPEUTICS |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL 60091 |
| Telephone | 8473880349 |
| Fax | — |
| — | |
| Website | https://www.monopartx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001645469 |
| Description | Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The companys pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Additional info from NASDAQ: |
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Read moreMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Read more(90% Positive) MONOPAR THERAPEUTICS (MNPR) Provides Update on centers for removing excess copper is compromised
Read moreNew Form SCHEDULE 13G - Monopar Therapeutics <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062250 <b>Size:</b> 13 KB
Read more(75% Positive) MONOPAR THERAPEUTICS (MNPR) Provides Update on Association for Wilson disease
Read moreMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Read moreMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Read moreNew Form SCHEDULE 13G/A - Monopar Therapeutics <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002922 <b>Size:</b> 12 KB
Read moreNew Form ARS - Monopar Therapeutics <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001437749-26-014221 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Monopar Therapeutics <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001437749-26-014218 <b>Size:</b> 396 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06980506 | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor … | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06980519 | MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor… | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-10-08 | 2027-01-01 | ClinicalTrials.gov |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid … | Phase1 | Solid Tumor, Adult | Recruiting | 2024-05-30 | 2026-04-01 | ClinicalTrials.gov |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Phase1 | Advanced Soft-tissue Sarcoma | Terminated | 2021-09-22 | 2024-05-13 | ClinicalTrials.gov |
| NCT04648020 | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral … | Phase2 | Chemoradiotherapy-Induced Severe Oral Mucositis | Terminated | 2021-02-11 | 2023-05-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Camsirubicin | Other | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| MNPR-101-PCTA-177Lu | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06617169 |
| MNPR-101-PCTA-177Lu | Other | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | Other | Preclinical | Cancer | AVAILABLE | NCT06980506 |
| PET/CT Diagnostic Imaging | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-DFO*-89Zr | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-PCTA-177Lu | BIOLOGICAL | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| Camsirubicin | DRUG | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| Placebo Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |